ÂÜÀòÂÒÂ×

Sir Marc Feldmann is a preeminent immunologist and an Emeritus Professor at the University of Oxford. With Sir Ravinder Maini, he identified TNF as a target. Trials of Infliximab (Remicade) they led were successful and prompted J&J’s $4.9B USD acquisition of Centocor. Remicade sales amount to more than $50B USD globally. Professor Sir Marc Feldmann is a Fellow of the Royal Society of Australian Academy and a Foreign Member of the US National Academy of Sciences; he was knighted in 2010 and received the Australian equivalent. He has received many accolades including the Albert Lasker Award, the Crafoord Prize, the Canada Gairdner Award, the Paul Janssen Award, and the Ernst Schering Award.